AXON and NTRP are trying to squeeze efficacy out someone else's drugs that previously failed and have nasty side effects. VTVT, which I also hold in my portfolio is interesting, not least for their diabetes efforts. The market cap of vTv is just about $50M again back in compliance with NASDAQ listing rules and sure to dilute probably several times.
I haven't check, but are also berating those companies on message boards or is it a special treat for AVXL?
News 
Market Data 
Discover 
AI
